The data was presented in a poster session at the International Herpesvirus Workshop (IHW) 2026 taking place in Montreal, Canada.

“We are excited by the new data which will guide the selection of antigens for a broadly protective CMV vaccine candidate and as such represent an important step forward for the EVX-V1 program. CMV remains a major clinical challenge, causing severe disease in immunocompromised individuals and infants, yet no licensed vaccine exists. EVX-V1 holds the potential to transform the future CMV treatment landscape,” says Birgitte Rønø, CSO and COO of Evaxion.

The new data show that the AI-Immunology™ discovered novel T-cell epitopes have the potential to improve control of acute infection, latency and reactivation in CMV-infected mice. This complements previous findings of the novel B-cell antigens significantly reducing viral infection in preclinical models and the optimized known structural B-cell antigens mediating superior viral neutralization.

EVX-V1

EVX-V1 is a next-generation, multi-component CMV vaccine program designed with AI-Immunology. It combines novel protective B-cell antigens and T-cell epitopes complemented by known optimized structural B-cell antigens.

Broader multi-targeted strategy

This broader multi-targeted strategy is expected to strengthen the protective potential of a future vaccine. The concept represents a scalable strategy for rational vaccine development across other herpesviruses.